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 64 
Abstract 65 
 66 
Background: The risk of postoperative pyoderma gangrenosum (PG) in patients with a known 67 
history of PG is unknown.  68 
 69 
Objective: To quantify risk and identify patient/procedure-related risk factors for postsurgical 70 
PG recurrence/exacerbation in patients with known history of PG.  71 
 72 
Methods: We retrospectively evaluated the likelihood of postsurgical PG 73 
recurrence/exacerbation for all patients with a confirmed diagnosis of PG at Brigham & 74 
Women’s Hospital and Massachusetts General Hospital from 2000-2015. 75 
 76 
Results: 5.5% (n=33) of procedures led to recurrence of PG in 15.1% (n=25) of patients. 77 
Compared to skin biopsy, small open surgeries had an adjusted odds ratio (aOR) of 8.65 (1.55, 78 
48.33) for PG recurrence/exacerbation; large open surgeries had an aOR of 5.97 (1.70, 21.00); 79 
and Mohs surgery/skin excision had an aOR of 6.47 (1.77, 23.61). PG chronically present at the 80 
time of procedure had an aOR of 4.58 (1.72, 12.22). Immunosuppression, time elapsed since 81 
original PG diagnosis, and procedure location did not significantly influence risk. 82 
 83 
Limitations: Our study is limited by its retrospective nature and relatively small sample size. 84 
 85 
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Conclusion: There is a small but clinically meaningful risk of postsurgical PG 86 
recurrence/exacerbation in patients with known history of PG; higher risks occur with more 87 
invasive procedures and chronically present PG. 88 
 89 
Keywords: Pyoderma gangrenosum, pathergy, risk factors, postoperative, recurrence, 90 
exacerbation, prophylaxis  91 
92 
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 93 
Capsule Summary 94 
 95 
• The risk of postoperative pyoderma gangrenosum (PG) in patients with history of PG is 96 
unknown.  97 
• 15.1% of patients experienced postsurgical PG recurrence/exacerbation; risk increased 98 
with more invasive procedures and chronic PG at the time of the procedure. 99 
• There is a small but clinically meaningful risk of postsurgical PG in patients with a 100 
known history of PG. 101 
102 
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 103 
Introduction 104 
Pyoderma gangrenosum (PG) is a neutrophilic process characterized by pathergy.1 Postoperative 105 
PG as a primary phenomenon has been characterized in the literature as being less likely 106 
associated with systemic diseases, with onset usually in the first week after the procedure is 107 
performed. 2,3 108 
 109 
Little is known about the risk for postoperative PG or recurrence/exacerbation of PG in patients 110 
with a known history of PG. Quantifying overall and procedure-specific risks for postoperative 111 
PG recurrence/exacerbation may affect medical decision making for patients with known history 112 
of PG, such as initiating prophylactic immunosuppression prior to procedures or 113 
avoiding/adjusting the timing of elective procedures. In this study, we aim to evaluate the risk for 114 
PG recurrence or exacerbation after different types of procedures in patients with a known 115 
history of PG. 116 
 117 
Methods 118 
We searched the Research Patient Data Repository, a database of the medical records of all 119 
patients seen at Partners Healthcare, for patients with PG who underwent procedures at the 120 
Brigham & Women’s Hospital and Massachusetts General Hospital from 2000-2015 using the 121 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 122 
(686.01) for pyoderma gangrenosum. Medical records of returned cases were individually 123 
reviewed to confirm a diagnosis of PG using previously described major and minor criteria 124 
suggestive of PG diagnosis.4 Relevant information regarding the original PG and all subsequent 125 
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surgical procedures underwent by the patient since the original PG diagnosis were extracted, 126 
with the primary outcome being PG exacerbation or recurrence within 30 days of the procedure. 127 
All data were managed using REDCap (Research Electronic Data Capture).5 Patients without a 128 
diagnosis of PG, subsequent procedures, or adequate clinical documentation were excluded.  129 
 130 
The types of procedures examined were 1) skin biopsies, 2) minimally invasive surgeries/small 131 
needle injections such as laparoscopies, arthroscopies, core-needle biopsies, and epidural 132 
injections, 3) small open surgeries such as thyroid surgeries and lumpectomies, 4) large open 133 
surgeries such as exploratory laparotomies and colectomies, and 5) Mohs surgery/skin excision 134 
and debridement (Supplementary Table 1). Chronically present PG at the time of surgery was 135 
defined as PG present for >1 year at the time of surgery or per clinician documentation. 136 
  137 
Procedure-level and patient-level PG recurrence rates were presented for patient demographics 138 
and clinical characteristics. Univariable and multivariable analysis was performed using logistic 139 
regression mixed models. Random intercepts were included in the regression models to account 140 
for possible within-person correlation for patients with multiple additional procedures. Variables 141 
with p<0.10 from the univariable analysis were included in the multivariable regression model. 142 
Adjusted and unadjusted odds ratios were calculated. All analyses were performed using SAS 143 
9.4 (Cary, NC).  This study was approved by the Partners Healthcare Institutional Review Board. 144 
 145 
Results 146 
 147 
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Of the 530 patients identified using ICD-9-CM codes for PG, 166 patients met inclusion criteria 148 
with a confirmed diagnosis of PG and subsequent procedures. Each patient underwent a median 149 
of 2 (interquartile range 1, 4) additional surgeries, for a total of 601 surgeries evaluated. The 150 
mean age was 52.8 years, and 80.1% (n=133) were women. The most common PG related 151 
comorbidity was inflammatory bowel disease (44.6%, n=74), and the most common location of 152 
original PG was on the lower extremities (57.8%, n=96) (Table 1). 153 
 154 
We found a total of 33 cases of postsurgical PG exacerbation/recurrence, occurring in 25 155 
patients, accounting for a recurrence rate of 5.5% (33/601) by procedure (Table 2) and 15.1% 156 
(25/166) by patient. Univariable analysis at the procedure level demonstrated that the 157 
exacerbation/recurrence rate was significantly associated with procedure type (p=0.022) and 158 
having chronically present PG at the time of procedure (p=0.041) (Table 2). Age ≥ 60 at time of 159 
surgery, sex, comorbidities, location of the original PG/surgery, location of surgery being at the 160 
same site as original PG, new/expanding/multifocal PG at the time of procedure, chronic or 161 
prophylactic immunosuppression were not statistically significant predictors of PG recurrence. 162 
Furthermore, time elapsed since the original PG and the additional surgery also were not 163 
associated with recurrence.  164 
 165 
Multivariable regression modeled exacerbation/recurrence as a function of age at time of 166 
surgery, chronically present PG, and procedure types (p<0.10).  Age ≥ 60 at time of surgery was 167 
associated with increased odds of PG recurrence and was of marginal statistical significance with 168 
an adjusted odds ratio (aOR) of 2.41 (95% CI: 0.92, 6.39).  Compared to risk of recurrence after 169 
skin biopsies, minimally invasive surgeries/small needle injections had similar risk for PG 170 
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recurrence with an aOR of 0.96 (95% CI: 0.16-5.60). Other procedure types were associated with 171 
increased odds of recurrence, with an aOR of 8.65 (95% CI: 1.55-48.33) for small open 172 
surgeries, an aOR of 5.97 (95% CI: 1.70-21.00) for large open surgeries, and an aOR of 6.47 173 
(95% CI: 1.77-23.61) for Mohs surgery/skin excision (Table 3). Chronically present PG at the 174 
time of surgery had an aOR of 4.58 (95% CI: 1.72-12.22). 175 
 176 
In a sensitivity analysis, we examined the relationship between patient-level characteristics at the 177 
time of first surgery with recurrence/exacerbation (n=166); age, gender, comorbidities, location 178 
of PG, multifocal ulcer, and chronic immunosuppression were not significantly associated with 179 
recurrence in this study.   180 
 181 
Discussion 182 
 183 
While pathergy associated with PG is a well-known phenomenon, our study found that the risk 184 
of postsurgical PG recurrence or exacerbation in patients with known history of PG is relatively 185 
low at 5.5% (33/601 surgeries). However, recurrence/exacerbation occurred in 15.1% (25/166 186 
patients) of our patients, suggesting that the per-patient risk for experiencing a recurrence of 187 
postsurgical PG recurrence/exacerbation is clinically relevant. Independent risk factors 188 
influencing PG recurrence/exacerbation post-procedure were procedure type and having chronic 189 
PG at the time of procedure. More invasive procedures such as small and large open surgeries, 190 
Mohs surgery/skin excision and debridement were more likely to be associated with PG 191 
recurrence.  192 
 193 
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This study builds on existing literature in PG by quantifying the risk of postsurgical PG 194 
recurrence/exacerbation in patients with known history of PG, which will help inform patients 195 
and physicians when assessing the risk of surgical procedures. In general, the greater the amount 196 
of tissue manipulation, the higher the likelihood of subsequent PG. This concept has face validity 197 
and is consistent with the current understanding of the pathophysiology of PG and pathergy, 198 
which is thought to involve dysfunction and up-regulation of neutrophil activities.6,7 Invasive 199 
surgeries are likely associated with more tissue manipulation, inflammation and surgical stress. 200 
Time elapsed between the original PG diagnosis and surgery, did not significantly influence 201 
recurrence risk, suggesting that the neutrophilic dysfunction of PG may be intrinsic to the host 202 
with limited change over time. 203 
 204 
Chronic or prophylactic immunosuppression leading up to surgery did not significantly influence 205 
recurrence risk in our study. However, this finding may reflect confounding by indication in that 206 
the use of chronic immunosuppression may be correlated with baseline severity of original PG, 207 
which was not a variable that we could account for due to lack of standardized clinical 208 
assessments.  As such, further studies are needed to evaluate the current practice or efficacy of 209 
prophylactic immunosuppression prior to procedures in patients with history of PG.  210 
 211 
While we identified independent predictors of recurrence risk on a procedure level, we did not 212 
find clinical factors that significantly predicted risk at the patient level. Smaller sample size on a 213 
per patient basis (25 patients with PG recurrences vs. 33 procedures complicated by PG 214 
recurrence) may have limited our ability to detect significant factors.  215 
 216 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
11
The results of this study must be interpreted in the context of our study design. Recurrent PG is 217 
rare, thereby limiting our ability to detect differences in recurrence risk between small open, 218 
large open, and Mohs surgery/skin excision procedures. The small sample sizes may also limit 219 
our detection of significance when examining risk factors at the patient level as discussed above. 220 
Future studies should confirm our findings in larger, multi-centered, prospective trials, especially 221 
evaluating whether risk factors identified in our study can be modified to decrease the risk of 222 
postsurgical PG recurrence/exacerbation. 223 
 224 
Conclusion: 225 
We conclude that there exists a small but clinically meaningful risk of postsurgical PG 226 
recurrence/exacerbation in patients with a known history of PG, with higher risks seen with more 227 
invasive procedures and in patients with chronically present PG at the time of surgery. Time 228 
elapsed between the original PG diagnosis, and surgery and prophylactic immunosuppression did 229 
not significantly affect the rate of PG recurrence.  230 
 231 
232 
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Table 1: Patient characteristics 264 
n (%) Overall 
n=166 
Age at PG diagnosis  
   < 60 97 (58.4) 
   ≥ 60 69 (41.6) 
Gender  
   Male 33 (19.9) 
   Female 133 (80.1) 
Comorbidities  
   Ulcerative colitis,  Crohn's disease 74 (44.6) 
   Hematologic disorder 22 (13.3) 
   Solid malignancy  16 (9.6) 
   Arthritis 46 (27.7) 
   Psoriasis  14 (8.4) 
   Diabetes  28 (16.9) 
   PVD  15 (9.0) 
   No relevant comorbidities  23 (13.9) 
   Other (pertaining to PG) 16 (9.6) 
Location of original PG  
   Head/neck 10 (6.0) 
   Trunk 65 (39.2) 
   Upper extremities 16 (9.6) 
   Groin/genitals 12 (7.2) 
   Lower extremities 96 (57.8) 
Number of additional surgeries  
   1 52 (31.3) 
   2-3 56 (33.7) 
   ≥ 4 58 (34.9) 
 265 
For results section:   266 
mean (SD) age: 52.8 (17.6) 267 
median (interquartile range) additional surgeries: 2 (1, 4) 268 
 269 
270 
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 271 
Table 2: Characteristics of additional surgeries and recurrence  272 
 No.  
surgeries 
n (%) with 
recurrences 
p-value 
Overall 601 33 (5.5)  
Age ≥ 60 at surgery 269  21 (7.8) 0.063 
Female 485  27 (5.6) 0.927 
Comorbidities    
   Ulcerative colitis,  Crohn's disease 322 14 (4.3) 0.317 
   Hematologic disorder 69 2 (2.9) 0.351 
   Solid malignancy  72 3 (4.2) 0.536 
   Arthritis  252 11 (4.4) 0.499 
   Psoriasis  66  5 (7.6) 0.469 
   Diabetes  115 10 (8.7) 0.173 
   PVD  58 1 (1.7) 0.239 
   No relevant comorbidities  68 5 (7.4) 0.551 
   Other (pertaining to PG) 46 3 (6.5) 0.698 
Location of original PG (may be more than one)    
   Head/neck 44 0 (0.0) -- 
   Trunk 246 16 (6.5) 0.441 
   Upper extremities 53 4 (7.5) 0.439 
   Groin/genitals 32 0 (0.0) -- 
   Lower extremities 351 17 (4.8) 0.385 
Time between original diagnosis and additional surgery    
   < 1 year 184 11 (6.0) 
0.765    1-2 years 125 6 (4.8) 
   ≥ 2 years 292 16 (5.5) 
Location of additional surgery    
   Head/neck 76 2 (2.6) 
0.755 
   Trunk 250 12 (4.8) 
   Upper extremities 44 3 (6.8) 
   Groin/genitals 86 5 (5.8) 
   Lower extremities 145 11 (7.6) 
Additional surgery in same location as original PG 180 8 (4.4) 0.318 
Multifocal ulcer at time of diagnosis 246 16 (6.5) 0.350 
Procedure type     
   Skin biopsy 209 6 (2.9) 
0.022 
   Minimally invasive surgeries / small needle 
injections* 
116 2 (1.7) 
   Small open surgeries 43 4 (9.3) 
   Large open surgeries 129 10 (7.8) 
   Mohs surgery / skin excision 104 11 (10.6) 
Chronic immunosuppression 313 15 (4.8) 0.637 
Started immunosuppression for procedure 5 1 (20.0) 0.216 
Chronically present PG at time of procedure 173 15 (8.7) 0.041 
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New/expanding PG at time of procedure 48 5 (10.4) 0.172 
*includes: cardiac catheterization, laparoscopy, arthroscopy, thoracoscopy, core needle biopsy, 273 
epidural or other small needle injection;  274 
p-values from generalized linear mixed models with random intercepts for patients with multiple 275 
additional procedures, binomial distribution and logit link 276 
277 
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 278 
Table 3: Odds ratios for associations between patient and procedure characteristics and 279 
recurrence 280 
 Unadjusted Odds 
Ratio  
(95% Confidence 
Interval) 
Adjusted Odds Ratio  
(95% Confidence 
Interval) 
Overall   
Age ≥ 60 at surgery 2.31 (0.96, 5.56) 2.41 (0.92, 6.39) 
Procedure type    
   Skin biopsy 1 (Reference) 1 (Reference) 
   Minimally invasive surgeries / small needle 
injections* 
0.62 (0.11, 3.50) 
0.96 (0.16, 5.60) 
   Small open surgeries 3.34 (0.66, 16.88) 8.65 (1.55, 48.33) † 
   Large open surgeries 3.57 (1.08, 11.84) † 5.97 (1.70, 21.00) ‡ 
   Mohs surgery/skin excision 5.92 (1.71, 20.44) ‡ 6.47 (1.77, 23.61) ‡ 
PG present at time of procedure 3.31 (1.41, 7.76) ‡ 4.58 (1.72, 12.22) ‡ 
*includes: cardiac catheterization, laparoscopy, arthroscopy, thoracoscopy, core needle biopsy, 281 
epidural or other small needle injection 282 
†p<0.05; ‡p<0.01 283 
Odds ratios from generalized linear mixed models with random intercepts for patients with 284 
multiple additional procedures, binomial distribution and logit link.  Variables with p<0.10 from 285 
univariable analysis included. 286 
287 
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 288 
Supplementary Table 1: Examples of procedures by category  289 
 290 
Skin Biopsies - Shave biopsy 
- Punch biopsy 
Minimally Invasive Surgeries/Small 
Needle Injections 
- Laparoscopy 
- Arthroscopy 
- Core-needle biopsy 
- Epidural injection 
- Percutaneous Endoscopic Gastrostomy 
(PEG) 
Small Open Surgeries - Thyroid surgery 
- Breast lumpectomy 
- Axillary lymphadenectomy 
- Fistulotomy and placement of seton 
- Carpal tunnel release/trigger finger 
release 
Large Open Surgeries - Exploratory laparotomy 
- Colectomy 
- Total knee/hip replacement 
- Ileostomy revisions/takedown 
- Below-the-knee/foot amputation 
Mohs Surgery/Skin Excision/Debridement - Mohs surgery 
- Skin excision 
- Wound debridement 
 291 
 292 
